Therapeutic area intelligence for Hematological Malignancies with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 0
Companies: 0

Companies

No related entities indexed yet.

Assets

No related entities indexed yet.

Recent signals(1)

ClinicalAugust 16, 2026

Study on mNGS for Diagnosing Invasive Fungal Disease in Hematological Malignancies

A single-center, open-label study is underway to evaluate the clinical performance of peripheral blood mNGS for diagnosing invasive fungal disease in patients with hematological malignancies.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Infectious Disease →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.